Why Tata Sons faces a listing mandate and how Tata Trusts hopes to avoid it
.webp)
Tata Trusts on Monday proposed merging Tata Electronics Systems Solutions (TESS) and Tata Consulting Engineers (TCE) into Tata Sons to avoid the holding company's public listing. The objective is to change the holding company’s business mix so that, according to the Trusts, it would no longer qualify as a non-banking financial company (NBDC) or a core investment company (CIC). The proposal still needs Tata Sons board approval and the Reserve Bank of India's (RBI’s) no-objection.
How Tata Sons got into the listing bind
The issue goes back to the RBI’s scale-based rules for NBFCs, introduced in 2021. The rules created an 'upper layer' for NBFCs that need closer regulatory oversight. Companies placed in this category are required to list within three years of being identified.
The RBI put Tata Sons in this upper layer in September 2022, which meant it had three years to list. The original deadline was September 2025. Instead of going public, Tata Sons tried a different route. It repaid its outstanding debt and, in 2024, asked the RBI to cancel its registration as a core investment company (CIC).
A CIC is a company whose main business is holding investments in other companies of the same group. Tata Sons had argued that, after repaying its debt, it no longer needed to remain registered as a CIC.
The RBI, however, kept Tata Sons in the upper layer in 2025 while it considered the application. This month, it rejected the request to surrender the CIC registration and directed Tata Sons to comply with the rules applicable to upper-layer NBFCs.
What is Tata Trusts proposing now?
Instead of asking the RBI to remove Tata Sons from the NBFC framework, Tata Trusts now wants to change the nature of the business housed within the holding group.
The Trusts has proposed merging two operating businesses, TESS and TCE, into Tata Sons. The reasoning is that these businesses would bring operating revenue and assets directly into the holding company, and the RBI’s rules look at what a company actually does and how its assets are structured. A CIC, for instance, must have at least 90 per cent of its net assets invested in specified group companies.
Tata Trusts says the proposed restructuring would change these ratios enough for Tata Sons to no longer meet the conditions for being treated as a CIC or an NBFC.
Why the stakes are high
The dispute is also about ownership and control. Tata Trusts holds about 66 per cent of Tata Sons and has opposed a listing. The Shapoorji Pallonji group, which owns about 18 per cent, has backed a public listing and argued that it would improve transparency and accountability.
The Tata Sons board also approved steps towards a listing during its September 17 board meeting.
What to watch next
The Trusts' proposal now has to go through the Tata Sons board. If the board approves the proposed merger, it would also need the RBI’s prior no-objection under the applicable rules.
The crucial question will then be whether the restructured Tata Sons actually falls outside the definitions that brought it under the NBFC and CIC framework in the first place.
Other Latest News
.webp)
President Donald Trump announced Essar-backed Mesabi Metallics' $18 billion investment to build a fully integrated American steel company, including what he called the "largest steel plant in American history" in Iowa.
The investment includes a proposed $15 billion steel complex in Iowa and about $3 billion invested in an iron ore mine and pelletizing facility in Minnesota.
.webp)
The US’s 100 per cent tariff on specified patented pharmaceutical products and their associated ingredients takes effect for more companies on Tuesday, but qualifying speciality medicines from India will be eligible for zero duty.
The US Department of Commerce’s Bureau of Industry and Security (BIS), in a September 23 notice published in the Federal Register, listed India among 20 jurisdictions eligible for zero-tariff treatment.
.webp)
Sun Pharmaceutical Industries has signed a global licensing deal with US-based LIB Therapeutics for Lerodalcibep, a once-monthly drug used to lower “bad” cholesterol, giving it exclusive rights to commercialise and manufacture the medicine outside the US and China, the company said in an exchange filing on Monday.
The deal gives Sun Pharma access to a $3.7 billion market for PCSK9 inhibitors, a class of cholesterol-lowering medicines.
.webp)
The Supreme Court on Monday took suo motu cognisance of the gangrape of a minor in a moving bus in Delhi-NCR, observing that such cases underline a systematic failure on the part of law enforcement authorities.
A bench of Justices JB Pardiwala and K Vinod Chandran said one cannot help but draw painful parallels to the Nirbhaya incident of 2012.
.webp)
Opposition INDIA bloc parties are likely to meet in New Delhi on September 30 to discuss concerns over the Election Commission and the Special Intensive Revision (SIR) of electoral rolls, besides other issues, sources said.
The proposed meeting comes amid increased coordination among opposition parties over the Election Commission following reports of differences within the poll panel over aspects of the SIR exercise.
.webp)
.webp)
.webp)
.webp)
.webp)
